{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:27:28Z","timestamp":1792099648378,"version":"4.4.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>An increasing number of immuno-therapeutic agents have proven efficacy in hepatocellular carcinoma (HCC). Inflammatory markers (c-reactive protein, interleukin-8 and inflammatory score) have been found to be prognostic factors in HCC patients. These inflammatory markers have demonstrated correlations with quality of life (QOL) disturbances in fatigue, appetite loss and nutritional concern. Type I interferon response triggered by HCC could be responsible for an inflammatory state and anorexia-cachexia syndrome leading to these specific QOL impairment. Peripheral blood Interferon Stimulated Gene 15 (<jats:italic>ISG15<\/jats:italic>) messenger ribonucleic acid (mRNA) transcript level, a biomarker for type I interferon response, was evaluated for its prognostic significance for overall survival (OS) in a prospective cohort of HCC patients. QOL measurement was employed to systemically capture and quantify patients\u2019 clinical manifestations for correlations with <jats:italic>ISG15<\/jats:italic> mRNA transcript level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical, QOL and laboratory data of 340 treatment na\u00efve HCC patients were collected at study entry. <jats:italic>ISG15<\/jats:italic> mRNA transcript levels in circulating leucocytes were quantified. Independent prognostic factors for OS were identified. Correlation analyses between <jats:italic>ISG15<\/jats:italic> mRNA transcript level and scores of QOL factors were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>High <jats:italic>ISG15<\/jats:italic> mRNA transcript level in circulating leucocytes was an independent prognostic factor for poor OS (hazard ratio 1.62 [1.23-2.15]; p-value&amp;lt;0.01). The median OS of patients with high <jats:italic>ISG15<\/jats:italic> gene expression was significantly shorter than those with low expression, 4.7 versus 14.3 months respectively (p-value&amp;lt;0.03). There were significant correlations between high <jats:italic>ISG15<\/jats:italic> mRNA transcript level and worse scores in QLQ-C30 fatigue, appetite loss and QLQ-HCC18 nutritional disturbances (p-values &amp;lt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Elevated <jats:italic>ISG15<\/jats:italic> mRNA transcript level in peripheral blood leucocytes was an independent poor prognostic factor for OS in HCC patients. Patients with higher <jats:italic>ISG15<\/jats:italic> gene expression, suggesting more intense type I interferon response, had significantly worse OS. High <jats:italic>ISG15<\/jats:italic> gene expression demonstrated significant correlations with QOL disturbances in fatigue, appetite loss and nutritional concern. These QOL factors could be capturing the anorexia-cachexia manifestations from interferon response induced by HCC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1589053","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:35Z","timestamp":1756268015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["ISG15 mRNA transcript level in circulating leucocytes prognostic of overall survival in hepatocellular carcinoma patients and correlated with quality of life disturbances involved in anorexia-cachexia"],"prefix":"10.3389","volume":"15","author":[{"given":"Leung","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson L. S.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin P.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C. H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-017-1621-6","article-title":"Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma","volume":"19","author":"Xiang","year":"2017","journal-title":"Clin Trans oncology: Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico"},{"key":"B4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.01.002","article-title":"Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma","volume":"144","author":"Hernandez-Gea","year":"2013","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S178482","article-title":"Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4048-0","article-title":"The C-reactive protein\/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma","volume":"22","author":"Kinoshita","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12885-016-2995-5","article-title":"Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data","volume":"17","author":"Li","year":"2017","journal-title":"BMC cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02190-0","article-title":"Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients","volume":"28","author":"Li","year":"2019","journal-title":"Qual Life Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2021.04.018","article-title":"Type I interferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in mice","volume":"95","author":"Stutte","year":"2021","journal-title":"Brain Behav Immun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1312","article-title":"Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma","volume":"19","author":"Motzer","year":"2001","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/BF00262586","article-title":"A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion","volume":"20","author":"Smith","year":"1987","journal-title":"Cancer chemotherapy Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100312","article-title":"Interferon alfa in the treatment of chronic viral hepatitis B and C","volume":"31","author":"Woo","year":"1997","journal-title":"Ann Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/v12030325","article-title":"Coxsackievirus B3 infection of human neural progenitor cells results in distinct expression patterns of innate immune genes","volume":"12","author":"Oh","year":"2020","journal-title":"Viruses"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903219040","article-title":"Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis","volume":"43","author":"Serrano-Fern\u00e1ndez","year":"2010","journal-title":"Autoimmunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.38219","article-title":"Investigating novel genes potentially involved in endometrial adenocarcinoma using next-generation sequencing and bioinformatic approaches","volume":"16","author":"Tang","year":"2019","journal-title":"Int J Med Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-017-0274-8","article-title":"Interferon-stimulated gene 15 expression in systemic lupus erythematosus: Diagnostic value and association with lymphocytopenia","volume":"77","author":"Yuan","year":"2018","journal-title":"Z Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"570909","DOI":"10.1155\/2013\/570909","article-title":"ISG15 inhibits IFN-\u03b1-resistant liver cancer cell growth","volume":"2013","author":"Wan","year":"2013","journal-title":"BioMed Res Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.09.033","article-title":"Emerging role of ISG15 in antiviral immunity","volume":"143","author":"Skaug","year":"2010","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63120","article-title":"Viperin restricts chikungunya virus replication and pathology","volume":"122","author":"Teng","year":"2012","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/cells11061011","article-title":"Multi-design differential expression profiling of COVID-19 lung autopsy specimens reveals significantly deregulated inflammatory pathways and SFTPC impaired transcription","volume":"11","author":"Fassan","year":"2022","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/0961203321992434","article-title":"Bioinformatic analysis of key biomarkers and immune filtration of skin biopsy in discoid lupus erythematosus","volume":"30","author":"Xiang","year":"2021","journal-title":"Lupus"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/ret1kg","article-title":"Increased expression of interferon regulated and antiviral response genes in CD31+\/CD102+ lung microvascular endothelial cells from systemic sclerosis patients with end-stage interstitial lung disease","volume":"39","author":"Piera-Velazquez","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2220984","DOI":"10.1080\/08916934.2023.2220984","article-title":"Patients with dermatomyositis shared partially similar transcriptome signature with COVID-19 infection","volume":"56","author":"Yang","year":"2023","journal-title":"Autoimmunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01477-8","article-title":"The transcription factor NRF2 enhances melanoma Malignancy by blocking differentiation and inducing COX2 expression","volume":"39","author":"Jessen","year":"2020","journal-title":"Oncogene"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0516","article-title":"Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma","volume":"19","author":"Zuo","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/vaccines12020153","article-title":"Unveiling the multifaceted roles of ISG15: from immunomodulation to therapeutic frontiers","volume":"12","author":"\u00c1lvarez","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3892\/or.2022.8321","article-title":"Interferon\u2212stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response","volume":"47","author":"Zhao","year":"2022","journal-title":"Oncol Rep"},{"key":"B32","article-title":"ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma","volume":"8","author":"Qiu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12967-023-04135-1","article-title":"ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma","volume":"21","author":"Qu","year":"2023","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2023.1.08","article-title":"The role of interferon-stimulated gene 15 in the occurence and progression of cervical squamous cell carcinoma","volume":"74","author":"Zhao","year":"2023","journal-title":"J Physiol Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbx009","article-title":"A simple way to detect disease-associated cellular molecular alterations from mixed-cell blood samples","volume":"19","author":"Hong","year":"2018","journal-title":"Brief Bioinform"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal Biochem"},{"key":"B37","first-page":"87","article-title":"Quantification strategies in real-time PCR","author":"Pfaffl","year":"2004"},{"key":"B38","doi-asserted-by":"publisher","first-page":"101249","DOI":"10.1016\/j.mam.2024.101249","article-title":"Improving the quality of quantitative polymerase chain reaction experiments: 15 years of MIQE","volume":"96","author":"Bustin","year":"2024","journal-title":"Mol Aspects Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.033","article-title":"Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18","volume":"40","author":"Blazeby","year":"2004","journal-title":"Eur J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl065","article-title":"Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma","volume":"17","author":"Yeo","year":"2006","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference","volume":"35","author":"Bruix","year":"2001","journal-title":"Eur Assoc Study Liver. J Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I interferon in chronic virus infection and cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","article-title":"Type I interferon response and innate immune sensing of cancer","volume":"34","author":"Fuertes","year":"2013","journal-title":"Trends Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/01.mco.0000134363.53782.cb","article-title":"Cancer anorexia-cachexia syndrome: cytokines and neuropeptides","volume":"7","author":"Ramos","year":"2004","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.052","article-title":"Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy","volume":"20","author":"Kirkwood","year":"2002","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3807","article-title":"Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial","volume":"28","author":"Verset","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-011-1129-9","article-title":"The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy","volume":"61","author":"Wood","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3390\/cancers15041237","article-title":"Targeting ubiquitin-like protein, ISG15, as a novel tumor associated antigen in colorectal cancer","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02422-9","article-title":"ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression","volume":"68","author":"Burks","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3372","article-title":"Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective","volume":"6","author":"Burks","year":"2015","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02017-8","article-title":"ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling","volume":"40","author":"Bolado-Carrancio","year":"2021","journal-title":"Oncogene"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17160","article-title":"Maximum efficacy of immune checkpoint inhibitors occurs in esophageal cancer patients with a low neutrophil-to-lymphocyte ratio and good performance status prior to treatment","volume":"44","author":"Hirasawa","year":"2024","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:36Z","timestamp":1756268016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":59,"alternative-id":["10.3389\/fonc.2025.1589053"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1589053","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1589053"}}